2024 Recommendations on the Optimal Use of Lipid-Lowering Therapy in Established Atherosclerotic Cardiovascular Disease and Following Acute Coronary Syndromes: A Position Paper of the International Lipid Expert Panel (ILEP)
Rattachement africain : us, pl, hr, xk, si, cz, it, sk, ro, il, de, hu, gr, cy, lv, ba, lt, ch, bg, ee, gb. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Atherosclerotic cardiovascular disease (ASCVD) and consequent acute coronary syndromes (ACS) are substantial contributors to morbidity and mortality across Europe. Fortunately, as much as two thirds of this disease's burden is modifiable, in particular by lipid-lowering therapy (LLT). Current guidelines are based on the sound premise that, with respect to low-density lipoprotein cholesterol (LDL-C), "lower is better for longer", and recent data have strongly emphasised the need for also "the earlier the better". In addition to statins, which have been available for several decades, ezetimibe, bempedoic acid (also as fixed dose combinations), and modulators of proprotein convertase subtilisin/kexin type 9 (PCSK9 inhibitors and inclisiran) are additionally very effective approaches to LLT, especially for those at very high and extremely high cardiovascular risk. In real life, however, clinical practice goals are still not met in a substantial proportion of patients (even in 70%). However, with the options we have available, we should render lipid disorders a rare disease. In April 2021, the International Lipid Expert Panel (ILEP) published its first position paper on the optimal use of LLT in post-ACS patients, which complemented the existing guidelines on the management of lipids in patients following ACS, which defined a group of "extremely high-risk" individuals and outlined scenarios where upfront combination therapy should be considered to improve access and adherence to LLT and, consequently, the therapy's effectiveness. These updated recommendations build on the previous work, considering developments in the evidential underpinning of combination LLT, ongoing education on the role of lipid disorder therapy, and changes in the availability of lipid-lowering drugs. Our aim is to provide a guide to address this unmet clinical need, to provide clear practical advice, whilst acknowledging the need for patient-centred care, and accounting for often large differences in the availability of LLTs between countries.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- 2024 Recommendations on the Optimal Use of Lipid-Lowering Therapy in Established Atherosclerotic Cardiovascular Disease and Following Acute Coronary Syndromes: A Position Paper of the International Lipid Expert Panel (ILEP)
- Date Crossref
- 04/11/2024
- Éditeur
- Springer Science and Business Media LLC
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Johns Hopkins University Department of Medicine pays non établi dans la noticeUniversité ou école supérieure
-
Johns Hopkins Medicine pays non établi dans la noticeÉtablissement de santé
-
Medical University of Lodz Department of Preventive Cardiology and Lipidology pays non établi dans la noticeUniversité ou école supérieure
-
Polish Mother’s Memorial Hospital Research Institute pays non établi dans la noticeÉtablissement de santé
-
University Hospital Centre Zagreb Department of Internal Medicine pays non établi dans la noticeÉtablissement de santé
-
Medical University of Silesia Department of Internal Medicine and Clinical Pharmacology pays non établi dans la noticeUniversité ou école supérieure
-
University Clinical Center of Kosovo pays non établi dans la noticeÉtablissement de santé
-
University of Prishtina pays non établi dans la noticeUniversité ou école supérieure
-
Ljubljana University Medical Centre pays non établi dans la noticeÉtablissement de santé
-
Charles University The 3rd Department of Internal Medicine-Metabolic Care and Gerontology pays non établi dans la noticeUniversité ou école supérieure
-
University Hospital Hradec Králové pays non établi dans la noticeÉtablissement de santé
-
University of Bologna Medical and Surgical Sciences Department pays non établi dans la noticeUniversité ou école supérieure
Department of Medicine — Johns Hopkins University, Johns Hopkins Medicine et Department of Preventive Cardiology and Lipidology — Medical University of Lodz, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.